Theravance Biopharma (TBPH) Misses Q2 EPS by 1c

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($1.06), $0.01 worse than the analyst estimate of ($1.05).

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
• Morgan Stanley sees quality stocks and AI adopters leading market